New Class of Antigen-Specific Cancer Active Immunotherapies based on an Off-the-Shelf Antigen Presenting Cell line (PDC*line)

Time: 1:30 pm
day: Day Two


  • PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells
  • PDC*line is much more potent to prime and boost antitumor antigen, including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
  • Applying the technology for any cancer